Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency (ADA-) is the first genetic disorder to be treated with gene therapy. Since 1990 when the first trial started for 2 patients with ADA- SCID, five clinical trials enrolling 11 patients have been conducted with different clinical approaches and the results obtained from these trials have recently been reported. According to these reports, T cell-directed gene transfer was useful in the treatment of ADA- SCID whereas the retroviral-mediated gene transfer to hematopoietic stem cells was insufficient for achievement of clinical benefits. This chapter reviews several crucial problems inherent in the current retroviral technology based on the clinical data observed in these pioneering ADA gene therapy trials and presents our new retroviral vector system for the next stem cell gene therapy.
Onodera
M
M
Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan. mk98d116@md.tsukuba.ac.jp
Nelson
D M
DM
Sakiyama
Y
Y
Candotti
F
F
Blaese
R M
RM
D000243:Adenosine Deaminase / Q000172:deficiency* / Q000235:genetics; D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D012190:Retroviridae / Q000235:genetics*; D016511:Severe Combined Immunodeficiency / Q000201:enzymology / Q000628:therapy*
D000243:Adenosine Deaminase